Results 201 to 210 of about 287,914 (297)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Genomic Confirmation of HLA-A*02:94N By Next-Generation Sequencing. [PDF]

HLA
Merschman J, Kreuter J, Millard K, Wakefield L, Gandhi MJ.   +4 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Characterisation of a New HLA Allele by Next-Generation Sequencing: HLA-C*06:424Q. [PDF]

HLA
Balakrishnan G, Shankar K, Vetriselvan R, Raut P, Agarwal N.   +4 more
europepmc   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential. [PDF]

FASEB J
Virk UY, Malik HA, Anwer M, Wilson J, Rahi MS, Wei MQ.   +5 more
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy. [PDF]

Exp Mol Med
Cho S, Lee J, Lee YM, Nam JH.
europepmc   +1 more source

Bioengineered microbiotic levodopa therapy improves cognition and reduces pathology in a rat model of Alzheimer's disease

British Journal of Pharmacology, EarlyView.
Background and Purpose Degeneration of the pontine noradrenergic and midbrain dopaminergic systems contributes to cognitive‐behavioural disturbances during the prodromal stages of Alzheimer's disease (AD). We developed a genetically engineered, programmable probiotic Escherichia coli Nissle 1917 strain (EcNrhaL‐DOPA) capable of producing L‐3,4 ...
Mona Abdelhamid, Piyush Padhi, Mahsa Gifani, John S. Beck, Jacob P. Thomas, Gargi Khadse, Catherine Kudela, Gregory J. Phillips, Anumantha G. Kanthasamy, Scott E. Counts   +9 more
wiley   +1 more source

Minor histocompatibility antigen TCR-T. [PDF]

Blood Adv
Krakow EF, Bleakley M.
europepmc   +1 more source